Drug Search Results

Remogliflozin

Alternative Names: remogliflozin, gsk-189075, gsk189075, gsk 189075
Latest Update: 2024-03-07
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SGLT2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Remogliflozin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes|Type 1 Diabetes

Phase 1: Type 2 Diabetes|Obesity|Weight Loss|Kidney Diseases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
BRID	P2	Completed	Type 2 Diabetes	2016-08-01	22%
KGI107465	P2	Completed	Type 1 Diabetes	2008-12-18
KG2110375	P2	Completed	Type 2 Diabetes	2008-06-05
2007-001463-29	P2	Completed	Type 2 Diabetes	2008-06-05

Recent News Events

Date	Type	Title
03/07/2024	PubMed	Quality by Design Tool Assessed Ultraperformance Liquid Chromatography Method for the Analysis of Remogliflozin and Teneligliptin in Oral Dosage Form.
09/30/2023	PubMed	Impacts of trelagliptin and remogliflozin alone and in combination with Alpha Lipoic Acid on cardiac function in streptozotocin-induced diabetes mellitus in rats.
08/28/2023	PubMed	Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
05/06/2022	News Article	Allergic Rhinitis Treatment Market Size Estimated to Reach $16.3 Billion by 2027
08/25/2021	News Article	Global Antidiabetic Drug Market Report 2021-2026 - Opportunities in New Innovations
05/11/2020	News Article	Global Anti-Diabetic Drugs Market (2020 to 2025) - Featuring AstraZeneca, Pfizer & Novo Nordisk Among Others
03/17/2020	News Article	Type 2 Diabetes Market Overview & Outlook, 2020 - SGLT-2 Inhibitors Hoping to Bolster Growth with Data & Label Additions for Pivotal HF and Chronic Kidney Disease (CKD) Trials

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions